Skip to main content
. 2015 Sep 29;19:349. doi: 10.1186/s13054-015-1066-7

Table 2.

Laboratory parameters at start of RCA-CVVHD treatment and end of observation

Normal liver function (bilirubin ≤2 mg/dl) Mild liver failure (bilirubin 2–7 mg/dl) Severe liver failure (bilirubin ≥7 mg/dl)
Start End Start End Start End
Number of patients 48 43 42
Total bilirubin (mg/dl) 0.8 ± 0.4 1.1 ± 0.8 3.6 ± 1.3 4.5 ± 3.2 18.4 ± 13.0 17.0 ± 11.2
Aspartate aminotransferase (U/L) 193 ± 454 196 ± 414 716 ± 1864 636 ± 2021 391 ± 1206 391 ± 1336
Alanine aminotransferase (U/L) 154 ± 602 104 ± 161 344 ± 766 361 ± 961 210 ± 476 199 ± 505
Creatinine (mg/dl) 3.5 ± 1.5 1.4 ± 0.7 2.7 ± 1.4 1.4 ± 0.6 2.3 ± 1.1 1.6 ± 1.9
Urea (mg/dl) 123 ± 75 53 ± 24 102 ± 59 49 ± 25 135 ± 69 74 ± 40
Sodium (mmol/L) 141 ± 5 142 ± 4 140 ± 6 142 ± 4 140 ± 7 140 ± 4
Potassium (mmol/L) 4.7 ± 0.7 4.3 ± 0.5 4.6 ± 0.8 4.4 ± 0.6 4.5 ± 0.7 4.3 ± 0.6
Phosphorus (mmol/L) 1.8 ± 0.9 0.8 ± 0.3 1.7 ± 0.8 0.8 ± 0.4 1.5 ± 0.7 1.0 ± 0.5
Magnesium (mmol/L) 1.1 ± 0.4 0.9 ± 0.1 1.0 ± 0.4 0.9 ± 0.2 1.0 ± 0.3 1.0 ± 0.2
Hematocrit (%) 30 ± 4 31. ±4 29 ± 5 30 ± 6 28 ± 5 29 ± 4
Platelet count (count/nl) 195 ± 170 159 ± 164 109 ± 85 92 ± 87 103 ± 91 98 ± 85
INR 1.7 ± 1.0 1.4 ± 0.7 1.5 ± 0.3 1.4 ± 0.4 1.8 ± 0.7 1.7 ± 0.6
aPTT (s) 52 ± 20 46 ± 10 50 ± 12 49 ± 17 59 ± 25 54 ± 16
Serum protein (g/dl) 4.9 ± 1.1 5.2 ± 1.0 4.8 ± 1.1 5.0 ± 1.0 5.2 ± 1.1 5.3 ± 1.2
Serum albumin (g/dl) 2.2 ± 0.6 2.2 ± 0.6 2.1 ± 0.6 2.3 ± 0.9 2.3 ± 0.6 2.3 ± 0.6
Total calcium (mmol/L) 2.0 ± 0.3 2.1 ± 0.2 2.0 ± 0.4 2.3 ± 0.3 2.1 ± 0.3 2.3 ± 0.3
Ratio total/ionized Ca2+ 1.8 ± 0.1 1.9 ± 0.1 1.8 ± 0.1 1.9 ± 0.2 1.8 ± 0.2 2.0 ± 0.3
Postfilter iCa (mmol/L) 0.27 ± 0.05 0.28 ± 0.03 0.27 ± 0.06 0.29 ± 0.03 0.30 ± 0.03 0.30 ± 0.02

aPTT activated partial thromboplastin time, iCa ionized calcium, INR international normalized ratio

Mean ± SD